{"ticker": {"uuid": "386c4ca9-c141-437e-8fb8-3d8d83cb4b5e", "symbol": "NGNE", "name": "Neurogene Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "(NGNE) Volatility Zones as Tactical Triggers", "summary": "This article analyzes Neoleukin Therapeutics Inc. (NASDAQ: NGNE) using AI models, highlighting strong sentiment across all horizons supporting an overweight bias. It outlines distinct institutional trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging\u2014tailored ", "url": "https://news.stocktradersdaily.com/news_release/35/NGNE_Volatility_Zones_as_Tactical_Triggers_071226075402_1783900442.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-12T19:41:38", "published_display": "12 Jul 2026 19:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene (NGNE) CFO sells 4,800 shares and retains 84,040 including RSUs", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPbGVEUmI0bW9YRWM0eXJQXzMzTnZfdkZEVkNXVW5WQUFFekZGZjJ2VDcwTEIzZ214MWpWNGVwVTYtT3djZjJ2NXZ4Wm85LXBBYktpb2h2c0Y0Tm5QelFqMlJUSlphSlpUUGdhZ2dJU0NLU2lhYW5vTUhmTkpzeGdyMVdGRDhJTEFSR3RMQk5ZMkVWT21Od0JxX3pueG9rb0NNcEdYY0dxS0NaMHM?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T01:20:28+00:00", "published_display": "08 Jul 2026 01:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/neurogene-announces-inducement-grants-under-200100094.html", "source_name": "Business Wire", "published_at": "2026-07-06T20:01:00+00:00", "published_display": "06 Jul 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene lures 6 new hires with stock options tied to July 6 close", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPaFE1NFJmRWpGbnZGQ3l3bWEzQWdpVUl4OUx1MkxEa3VEUFJHLTY1OExfeTJ3YXIzSXpTanpYQXZfbVZsemZBZ0pxRVZ6d1lZcUx3dURjLUpMZlRvbmFHNGhwLUU4UzBNOFBhMmh6M3NhdkljWjNlZFJxVE9rYkdieVRvZXRvZkx0ci10OXNQUlNGVEloTll4VUk3cm9pZlRQVk1ZeVh0V0JzRU1mSDQtZ0hjV3BVTndjNGxkNXJrUGI?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Neurogene Inc. \u2013 NASDAQ:NGNE", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNQ0dHUWdJRHFtRmtTUDdHVHdwMF9Eczlrd1VwYVY2d2gtSlh1ZGY1OHF3c3NpY0hoR2hOTzhEalBLdEl5SkNUS3JwZHhwendGTzNhVWNEVGtPTnlORU5Rb19oMkt1SkhKUXJ4Y0YxbmZGMnlySGVDWC1BYnJZRVFoaEthNTRlTzY5U1plZ2FjSGhkR3QtTm1aVElLUlJFeDIwOFpacUFOUDR1Wmdm?oc=5", "source_name": "TradingView", "published_at": "2026-07-04T12:01:04+00:00", "published_display": "04 Jul 2026 12:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene (NGNE) secures $134.8M, extending cash runway into 2029", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPNXE4SEtJZDJIazJJNk8xOTYxVWtVQWlZNmVJZENkQm96MFhPVlRKY0lRTkFUVGp5YUE5NkQ0NTJBcF9EQ25tVmxka1QwSUctcmVMZjlSRGdtRUZERVYwSnNkOHBSUW1icVhjWlpyUG5BWjh1T0pLRG5Oc0ZzQjg0RXF3RTMwM3RhRHB5ajZFeEtSb3VkdUZxWEhMVnY4ZTZ6R1hENA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene (NGNE) CFO\u2019s 4,800-share sale under 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNS29TdXltbEFTRkdRRGR3Nlp1UTNuQ3V3WEl0ekFWbThkcmpJVDVSWFRsaTNfbG8zLWNURUx1ckl6eUpnd3A5N3N4Q0tUM2U4ZXVfcFd3WWlxMlVMNjhIOENDNEhadGRCTXNaREYybWI3MDNhUjBUYURlQlVDZjlzOUZQSFV6eXVDZTloWVZlNXdoVnZGaHB6VWl5ZHRmYXdTWTV5aEd1ZlVjZ3M?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price-Driven Insight from (NGNE) for Rule-Based Strategy", "summary": "This article provides a price-driven insight for Neoleukin Therapeutics Inc. (NASDAQ: NGNE) based on AI-generated signals for July 01, 2026. It highlights strong sentiment supporting an overweight bias, an ongoing breakout, and no resistance levels above the current price. The an", "url": "https://news.stocktradersdaily.com/news_release/39/Price-Driven_Insight_from_NGNE_for_Rule-Based_Strategy_070126064601_1782945961.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-01T19:09:11", "published_display": "01 Jul 2026 19:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene Prices $125 Million Public Offering", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/neurogene-prices-125-million-public-115119968.html", "source_name": "MT Newswires", "published_at": "2026-07-01T11:51:19+00:00", "published_display": "01 Jul 2026 11:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene Inc. Announces Pricing of $125 Million Public Offering", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/neurogene-inc-announces-pricing-125-110000050.html", "source_name": "Business Wire", "published_at": "2026-07-01T11:00:00+00:00", "published_display": "01 Jul 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene (NGNE) sells 3.5M shares, pre-funded warrants in $117M deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPUGZwWGpwc3RpMmhWVmZQNm1GVFlGdHNRalQ1MW1kYWxTei11TUVLT2hFcGU2ZERNNldvb0dVOUg5SWJ5aXRDTTJRMGFNRjhWU2ktcHJxVE9adWFDNk1lOEh0dFFJcVFVNEVkRlE2RXpRejk4RU5tejV5X2Qyc3puZHhSdUJCaHdBOS1VdTJMcXlrUDVXRUNoaWFrdGMzajFHeGk2bWJZOFU0UnhhUHRWRnNhU01uQmFGUjdN?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene Inc. (NGNE) Discusses Updated Phase 1/2 Data for NGN-401 Gene Therapy in Rett Syndrome - Slideshow", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOYXpWdUdqUnlWMklpTTZBZnV2VF9LdVIzeE00TThnODJnZzdKbXExMlFGbXNnZVc4Skh0cjdJTkg5NHBCaml0ZFJFX2FRdkc4VTdRSVJ0c2ZSdmRPWjN1ZUY1a0E1T2pUVloxdmpaa1RTWjBjc3JxeWV6SFY5RkhDUndOSnBuWkdjTTlvdVRSVndiZmtaRDdzUDVjOW1USE9BN0JYNFk3bDQ3ZHl1SGpySThzRmJBdE9BUUs2Z1N5bGxhcXNyN2FXUDdR?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene locks in $125M stock sale, closing expected July 2", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOR2twa2hIeE84MlRhWHI2dm5UOXRlUUtfbDVNVjhLb1NxZTZfRjVIZ0NNWFdzemR1ZE5iQTlsNUE1YXVoSW1CZnM4Q2VDYkFIVlFRT3hZejJyUU0zVDAxQTkyX0xqQ0dBSllIS3RUN25pckFHdFZHZG9WbkRtbjRpTjNmVjNEZkdlRGFTaHVucVlzcXo1UFM0UXYxZkZlUEFUeTNlS0NzN3Y0OS1M?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene Launches Public Offering", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/neurogene-launches-public-offering-202515977.html", "source_name": "MT Newswires", "published_at": "2026-06-30T20:25:15+00:00", "published_display": "30 Jun 2026 20:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene Inc. Announces Proposed Public Offering", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/neurogene-inc-announces-proposed-public-200100179.html", "source_name": "Business Wire", "published_at": "2026-06-30T20:01:00+00:00", "published_display": "30 Jun 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene seeks new funding for NGN-401 development", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPYnJFZC1GYW14bS1rY3hYb1JvczAzQkFPM3h2b3hkbTZXcTJlcTNycnZoUGFac2xEQnhZWWJ1VkFxaVA0NXRKT1BMN3dmRXdhdVl6TkNURVNWMkNBdlpyaWF3NzRMQXd3bkJXOU1QVC1JNVhSeTIxMDNMb1A2U0ItOFliaTRydUhyWHcyWUJGNWlXV0thcXcwTGxR?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene stock falls on public offering announcement", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOV0RRT3BWOHhhc3JkbGFCVTljXzE3YUZnbWtwdjhVY29sRnNtSk9VZ3FsdUpLRHpyRkFTaW53ZnZKbWRQTEVPRVFQazQ5X1ZrNXFCVXhDVnJXcWN2aUsxalE3Y0dCZ1VzSTZackxycENWcFhxVjJiVWZPelZLWnVuQ1I5Q3RHMDVGd01HLUlYak1NZXhSTGU1SnhleXp0SFpsNXQ5cHJteDl5aUk3NURWUklqUTZ2dw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/neurogene-reports-positive-long-term-110000835.html", "source_name": "Business Wire", "published_at": "2026-06-29T11:00:00+00:00", "published_display": "29 Jun 2026 11:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NGNE SEC Filings - Neurogene 10-K, 10-Q, 8-K Forms", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE1OX0t4c3F1TkdSc3ZfSndUenZzY2Rxbm1Vejh5UjM0X3Q5UHFNXzI3MXBRcjJQa2ljTkpCYlpPbWhzVV9DWEtNT01QTGRQWTA2R0htbHlCcklNZzh2ejJwcXJ4R1hHdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-21T08:43:54+00:00", "published_display": "21 Jun 2026 08:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(NGNE) Price Dynamics and Execution-Aware Positioning", "summary": "This article analyzes Neoleukin Therapeutics Inc. (NASDAQ: NGNE), highlighting strong sentiment across all horizons supporting an overweight bias. It outlines detailed institutional trading strategies, including long, momentum breakout, and short setups, with specific entry, targ", "url": "https://news.stocktradersdaily.com/news_release/1/NGNE_Price_Dynamics_and_Execution-Aware_Positioning_062026053402_1781991242.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-20T17:34:00", "published_display": "20 Jun 2026 17:34", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene (NGNE) director receives 12,050 fully vested stock options at $20.40", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQSU1IZWpkcmxDd3AtRmVMcS1paW12US15V0ExSXBFclBsaUtzbFhrajB5WUF4ZGI3TDh2azE4RFduRkNSeXcxVDFQVjEtVTl2aHEzMkZ3Qy1vYU1Jc1ZMVGJhQ2NqM2h5YndVOXVVV1U5TmZ0VHpXLUxBbG8zdG83SFR3czI2U2RYZndLZ0R3MHpnNWFablBRMHB1YkRuaEZ1bVIzMm5zTXdiTTVPb1lBU3g2RUs0ZFdX?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene Completes Enrollment in Embolden Trial of NGN-401", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/neurogene-completes-enrollment-embolden-trial-125433618.html", "source_name": "MT Newswires", "published_at": "2026-06-08T12:54:33+00:00", "published_display": "08 Jun 2026 12:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene Announces Successful Completion of Dosing in Embolden\u2122 Registrational Trial of NGN-401 for Rett Syndrome", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/neurogene-announces-successful-completion-dosing-113000090.html", "source_name": "Business Wire", "published_at": "2026-06-08T11:30:00+00:00", "published_display": "08 Jun 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "25 girls receive Neurogene\u2019s one-time gene therapy in key Rett syndrome trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPcktySlpxN2Z6a3laRWF4ZDZPR3dZbjZsTVc3RDJVakZoYlA5cVlaaTVDRVBKTW5kbXJucFNJc1BuUlNtUTRzSmJNTG02OVF1Q1dtUG41UVY2U0JRZnVLRzgxU1JjSlZydnExdi1XWUk3blBNdkVuR1c4b1N4d3h6eTVyME1YVExlWjBLMk5SOFpzakZSTGJRcF9NQm5McVJwSnNHRnJMMHRkRUJObWhRYTg3MW5fRl9FZ05rZmt3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two new Neurogene hires get options on 17,045 company shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPYmt3RGZaWG9BaWpmX1IzeE5TWEpQRjM2LTFMNE8yN1JzZDdSU09uN3o5cHViQVlrSU1zbTNiTmotbjF0QkptbDNEeDdlR2ZldGtNT1FXaGVfaXVBdXdlV1p4RmFRZ2hNcWVmOW5teFdaQjdGRlp6dzZmRG9MbXdrTHI2TGYzbjBfd1dwODBUQlpFR3hqUU1kMWlaQ2xscURjajZFR2xLVzVobGMzRVg2dVJ4RmJSWmVJNkJzbi1FM3c?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(NGNE) Movement as an Input in Quant Signal Sets", "summary": "This article analyzes Neoleukin Therapeutics Inc. (NASDAQ: NGNE) using AI models, indicating a neutral near-term outlook with potential mid-term strong sentiment stalling. It highlights a significant short setup with a 79.2:1 risk-reward ratio, targeting a 23.2% downside. The rep", "url": "https://news.stocktradersdaily.com/news_release/90/NGNE_Movement_as_an_Input_in_Quant_Signal_Sets_051826014802_1779126482.html", "source_name": "Stock Traders Daily", "published_at": "2026-05-18T13:48:00", "published_display": "18 May 2026 13:48", "sentiment": "negative", "sentiment_pct": 38, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Neurogene Inc. Stock 12\u2011Month Price Target Raised to $77.86, Implies 147% Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNTzZZaFlGVUhWMjRlU2dfcW1JQnNBc0sxR290ZUNqdTRsN2NsdE40ZzNXS01GeDg0U0pNRV9XalRpaTFqM2ktVEc2TDFubGd0V1V6X014UU9MUEVHZDF6RVF2Vkx1OVF0d2lwU3NidWRDMks3SE85emtOcTZlMUxFQUsxZWFTTkRlSnhLMEFlZWpQMGVVZ1RKWUlESzRRVlFnRkNoTW5TN2wteW1DbUotaW1iZF9Id0FVZ3paQnMwRnl3dU56dE8zYVBDdDZZaWFKMl9oQg?oc=5", "source_name": "TradingView", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 80, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/news/neurogene-q1-earnings-snapshot-202515103.html", "source_name": "Associated Press", "published_at": "2026-05-12T20:25:15+00:00", "published_display": "12 May 2026 20:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Neurogene Insider Sold Shares Worth $300,043, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/neurogene-insider-sold-shares-worth-155621031.html", "source_name": "MT Newswires", "published_at": "2026-05-08T15:56:21+00:00", "published_display": "08 May 2026 15:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene (NGNE) CFO executes 9,600-share 10b5-1 stock sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQcEtsdFFOU1gxTENzdExEVGUwT2JPSW1mZE5GalpPdXZUaWVLUFpld0JhUGtjbTdlVW1uNVNQZHlTWDhZTzVqWHh1cEE5cENNYjAxQTQtZHF1QXVLSGhfd2RxYWVad29oQVhkcXFuenNMNUwtSFAxS284ZndqanpsckpTcWNMWWpJemF6OTdlV3drTC1Nb2J4VWxWS3ZaMDlpNE1FdkZBZlBtRk0?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liquidity Mapping Around (NGNE) Price Events", "summary": "This article from Stock Traders Daily provides a detailed analysis of Neoleukin Therapeutics Inc. (NASDAQ: NGNE) price events. It highlights the potential for sustained positive sentiment, notes elevated downside risk due to a lack of long-term support, and outlines institutional", "url": "https://news.stocktradersdaily.com/news_release/98/Liquidity_Mapping_Around_NGNE_Price_Events_050726124002_1778172002.html", "source_name": "Stock Traders Daily", "published_at": "2026-05-07T12:40:06", "published_display": "07 May 2026 12:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene (NGNE) CCO granted 120,000 non-qualified stock options at $28.94", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNeWN5MFFBQ0RHSUFoS09wbUZpWmhzU0JaN3R0MzBwOExjRk5fRHVISi1CRmNQMVptellnM3p0TUNzMlFGZy1nZk1nNDZaSTY0ZS1wd3Z0YjFaSmV2OHBwUV94bTlQZUh1TUJpbmdmQkg2QUxJOWtvbVlvaFlJOFNjZ2RtSEpyd3kwSDB2bzRSYjhTNFVVeEdxN2FsUi1XNFo4aUxIQTZ6UzJSVUk?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cvijic to Sell 14,400 Neurogene Shares (NGNE) via J.P. Morgan", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPbmtaTkM2Mlh4bVVfdHJsZ3AwZ0t4WUJDRmgxdlV3Vkh3dnlHQWlEN081QWRmT1lycmRiV3V6VnB1MG96ckJxdjhkS3ZSR0hIREo0M1hsNWl3SmVDQzVJdG1wRjBPLXgtTTRZcEw2VTlUQmdTVC1iYTdJQ251aFVKQlZBTWItRHdsS194bWcybVpFUnZC?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Neurogene (NASDAQ:NGNE) Can Afford To Drive Business Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOUEw1dU1UaVV1bGZxNnVRNHY0U29iQnhkWVl4cHEwOW9QeHZRVWVpRVZteXJFYTBvOUhFQ1ctN0JJRzNqWS15MWhMbmFNRjFnUFRiM3Bwd0xieXlrd2FEUGdpT0ZEazktd0pQTFBKQkNPRkFoazF1UHBPU0NhRGFsQlFMbWVtU3k4Z3lMbFNnSXgtemI5b1ViNDhFZEdXZUs4?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Companies Like Neurogene (NASDAQ:NGNE) Are In A Position To Invest In Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxQX1hhWlF1ckNsaVI3SDlRT2xFWWp1ZF8yVjh0Nm9HOFlrbm1qQ0RsZ1FQbW5qb2llTWRkX0syazFSUnZpMk52RTJ0b0Q3TkU0eERwelRHWTM0TkdJZXpPczNmRHhlaHYxUERjVk9CNE1SZ0RhMENWOUdhMkYtSGZPbTZ5UC1pWjl6emxOckZOYkQta3dhRWozTy1HTE5JOEdnckxXQ18yd1BLZWVyWHFibVk3VWZwQlhtc2FnNVlwT3pYTmw5NzNOOEx4Wm4xUVJPblV4ZUVQYzllLW_SAeABQVVfeXFMTkFyTzg1NVdBN1NLejhhTHhUeWdZMGFrSUlaalhxbV9lcDBxeUNZY2hEbzRINkhNZEdTNDF3QWlLazZxTVVuTUE2cnpYSmh0c292MGNPenJyN3lRWVJOWEowQ0UtNTdfUjBMUkpiUmdnNkpIX0pWWjVOLUJKVnRmeU9nTTBGR1dLbXh6TU5weDJCbnpCYjRyckpvZUZuRlZEaFFMVjlhd1RLTW9xRHBVeHBuZE83eElqZnVHYTg1YnB1RF9EajVBOWJ6cUlwck16dWdkMTlLSktfbEZGTmRqU0w?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding Momentum Shifts in (NGNE)", "summary": "This article analyzes Neoleukin Therapeutics Inc. (NASDAQ: NGNE) using AI models to identify momentum shifts. It highlights weak near-term sentiment challenging long-term strength and outlines three distinct trading strategies with specific entry, target, and stop-loss zones. The", "url": "https://news.stocktradersdaily.com/news_release/139/Understanding_Momentum_Shifts_in_NGNE_041526102402_1776263042.html", "source_name": "Stock Traders Daily", "published_at": "2026-04-15T10:24:00", "published_display": "15 Apr 2026 10:24", "sentiment": "negative", "sentiment_pct": 29, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Discipline and Rules-Based Execution in NGNE Response", "summary": "This article analyzes Neoleukin Therapeutics Inc. (NASDAQ: NGNE) using AI models to provide trading strategies. It notes weak near and mid-term sentiment but a strong long-term outlook, identifying an exceptional risk-reward setup. The analysis offers specific entry, target, and ", "url": "https://news.stocktradersdaily.com/news_release/14/Discipline_and_Rules-Based_Execution_in_NGNE_Response_032426080602_1774353962.html", "source_name": "Stock Traders Daily", "published_at": "2026-03-24T08:06:00", "published_display": "24 Mar 2026 08:06", "sentiment": "negative", "sentiment_pct": 40, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(NGNE) Movement Within Algorithmic Entry Frameworks", "summary": "The article provides an algorithmic analysis of Neoleukin Therapeutics Inc. (NASDAQ: NGNE), highlighting strong sentiment across all horizons and an overweight bias for the stock. It details various institutional trading strategies including position, momentum breakout, and risk ", "url": "https://news.stocktradersdaily.com/news_release/81/NGNE_Movement_Within_Algorithmic_Entry_Frameworks_030226045002_1772445002.html", "source_name": "Stock Traders Daily", "published_at": "2026-03-02T04:50:00", "published_display": "02 Mar 2026 04:50", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How (NGNE) Movements Inform Risk Allocation Models", "summary": "This article analyzes Neoleukin Therapeutics Inc. (NASDAQ: NGNE) using AI models, highlighting a mixed sentiment with positive near-term but weak mid-term outlook within a long-term strength context. It provides three distinct institutional trading strategies\u2014Position Trading, Mo", "url": "https://news.stocktradersdaily.com/news_release/24/How_NGNE_Movements_Inform_Risk_Allocation_Models_021926032201_1771489321.html", "source_name": "Stock Traders Daily", "published_at": "2026-02-19T03:22:00", "published_display": "19 Feb 2026 03:22", "sentiment": "positive", "sentiment_pct": 71, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(NGNE) and the Role of Price-Sensitive Allocations", "summary": "This article provides an AI-generated analysis of Neoleukin Therapeutics Inc. (NASDAQ: NGNE), highlighting weak near and mid-term sentiment but a strong long-term outlook. It presents three distinct institutional trading strategies\u2014Position Trading, Momentum Breakout, and Risk He", "url": "https://news.stocktradersdaily.com/news_release/78/NGNE_and_the_Role_of_Price-Sensitive_Allocations_011626115802_1768625883.html", "source_name": "Stock Traders Daily", "published_at": "2026-01-16T23:58:00", "published_display": "16 Jan 2026 23:58", "sentiment": "negative", "sentiment_pct": 38, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Responsive Playbooks and the NGNE Inflection", "summary": "This article provides an AI-driven analysis of Neoleukin Therapeutics Inc. (NASDAQ: NGNE), highlighting weak near-term sentiment despite potential long-term strength. It presents specific trading strategies (Position, Momentum Breakout, Risk Hedging) with entry, target, and stop-", "url": "https://news.stocktradersdaily.com/news_release/23/Responsive_Playbooks_and_the_NGNE_Inflection_010526105002_1767671402.html", "source_name": "Stock Traders Daily", "published_at": "2026-01-05T22:50:00", "published_display": "05 Jan 2026 22:50", "sentiment": "negative", "sentiment_pct": 30, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why (NGNE) Price Action Is Critical for Tactical Trading", "summary": "This article analyzes Neoleukin Therapeutics Inc. (NASDAQ: NGNE) price action, highlighting a strong near-term sentiment while a mid-channel oscillation pattern is in play. The analysis identifies an exceptional risk-reward short setup and outlines three distinct AI-generated tra", "url": "https://news.stocktradersdaily.com/news_release/39/Why_NGNE_Price_Action_Is_Critical_for_Tactical_Trading_121425073202_1765758722.html", "source_name": "Stock Traders Daily", "published_at": "2025-12-14T19:32:00", "published_display": "14 Dec 2025 19:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Behavioral Patterns of NGNE and Institutional Flows", "summary": "This article analyzes Neoleukin Therapeutics Inc. (NASDAQ: NGNE) using AI models, highlighting a near-term weak sentiment despite mid-term strength and a broader long-term weak bias. It identifies a significant risk-reward short setup with a target of 41.6% downside versus 0.3% r", "url": "https://news.stocktradersdaily.com/news_release/15/Behavioral_Patterns_of_NGNE_and_Institutional_Flows_102325015602_1761242162.html", "source_name": "Stock Traders Daily", "published_at": "2025-10-23T13:56:00", "published_display": "23 Oct 2025 13:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene Announces Oversubscribed $200 Million Private Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOcUdxZ1NTOWh5Tm9yZExSVGZiOVJnV0tfZ18talJibnNKTjVyQ2NhMlBKUHluZy1xanRUeXJ6N0ZIODlZRWlBeDJ5SkFwbDdvM0Q0bnRNNXUwMndBRW5vRlhHYno5TWdVZ2RzTC14YTBvN2htRmxmUllySkxBa2F1ZG51bHJyb0djb29UR3FkaC1VTUN0WG5SQUtwX2tZVUlfM1R5V280dzFibzB2U2hsNWo3MUx3QkljX2cxMFBIT2ZoUQ?oc=5", "source_name": "Business Wire", "published_at": "2024-11-04T08:00:00+00:00", "published_display": "04 Nov 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene Stock: Gene Therapy Specialist May Break Chain Of Failed Mergers (NASDAQ:NGNE)", "summary": "Neurogene Inc., a clinical-stage gene therapy company, has seen its share price rise significantly since its Nasdaq debut in December 2023. The company is advancing two drug candidates, NGN-401 for Rett Syndrome and NGN-101 for CLN5 Batten Disease, with key milestones anticipated", "url": "https://seekingalpha.com/article/4680543-neurogene-stock-gene-therapy-specialist-may-break-chain-of-failed-mergers", "source_name": "Seeking Alpha", "published_at": "2024-03-26T14:13:00", "published_display": "26 Mar 2024 14:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene (NGNE) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9FVVBSb3FQdzlGZjRwdkMtZF9NVnBZS0J3VVBpOHVrWTdrM1VlMzVuZmR5QWhseTFOOXlYX2RDcUFtdVlDaS1UVGx6dFRKVmlWajJCdnRiRllqZw?oc=5", "source_name": "MarketBeat", "published_at": "2023-12-26T19:49:16+00:00", "published_display": "26 Dec 2023 19:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million", "summary": "Neurogene announced the closing of its merger with Neoleukin Therapeutics and a concurrent oversubscribed private placement of $95 million. The newly combined company, trading on NASDAQ as \"NGNE,\" now has approximately $200 million in cash, which is expected to fund its operation", "url": "https://aijourn.com/neurogene-announces-closing-of-merger-with-neoleukin-therapeutics-and-concurrent-private-placement-of-95-million/", "source_name": "The AI Journal", "published_at": "2023-12-19T18:10:13", "published_display": "19 Dec 2023 18:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kahn Swick & Foti, LLC Investigates Merger of Neoleukin Therapeutics, Inc. - NLTX", "summary": "Kahn Swick & Foti, LLC (KSF), led by former Louisiana Attorney General Charles C. Foti, Jr., is investigating the proposed merger of Neoleukin Therapeutics, Inc. (NLTX) with Neurogene Inc. The investigation aims to determine if the merger adequately values Neoleukin and if the pr", "url": "https://markets.financialcontent.com/fatpitch.financials/article/bizwire-2023-7-25-neoleukin-therapeutics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-and-foti-llc-investigates-merger-of-neoleukin-therapeutics-inc-nltx", "source_name": "FinancialContent", "published_at": "2023-07-25T10:49:00", "published_display": "25 Jul 2023 10:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neoleukin Therapeutics To Merge With Neurogene: Creates Biotech Firm Focused On Genetic Medicines For Neu", "summary": "Neoleukin Therapeutics and Neurogene are merging to form a biotech firm focused on genetic medicines for neurological diseases. The combined company, to be named Neurogene Inc., will focus on advancing Neurogene's pipeline, including NGN-401 for Rett syndrome, and is expected to ", "url": "https://www.benzinga.com/general/biotech/23/07/33263292/neoleukin-therapeutics-to-merge-with-neurogene-creates-biotech-firm-focused-on-genetic-medicines-", "source_name": "Benzinga", "published_at": "2023-07-18T18:39:02", "published_display": "18 Jul 2023 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene and Neoleukin Announce Merger", "summary": "Neurogene Inc. and Neoleukin Therapeutics, Inc. have announced a definitive merger agreement, with the combined entity set to operate as \u201cNeurogene Inc.\u201d The merger also involves an oversubscribed US$95 million private financing, projecting approximately US$200 million in cash fo", "url": "https://www.pharmtech.com/view/neurogene-and-neoleukin-announce-merger", "source_name": "PharmTech.com", "published_at": "2023-07-18T14:11:09", "published_display": "18 Jul 2023 14:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene and Neoleukin Announce Definitive Merger Agreement", "summary": "Neurogene and Neoleukin Therapeutics have entered into a definitive merger agreement to form a Nasdaq-listed biotech company focused on genetic medicines for neurological diseases. The combined entity is expected to have approximately $200 million in cash, including a $95 million", "url": "https://www.globenewswire.com/news-release/2023/07/18/2706252/0/en/Neurogene-and-Neoleukin-Announce-Definitive-Merger-Agreement.html", "source_name": "GlobeNewswire", "published_at": "2023-07-18T07:39:08", "published_display": "18 Jul 2023 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "(NGNE) Volatility Zones as Tactical Triggers", "summary": "This article analyzes Neoleukin Therapeutics Inc. (NASDAQ: NGNE) using AI models, highlighting strong sentiment across all horizons supporting an overweight bias. It outlines distinct institutional trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging\u2014tailored ", "url": "https://news.stocktradersdaily.com/news_release/35/NGNE_Volatility_Zones_as_Tactical_Triggers_071226075402_1783900442.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-12T19:41:38", "published_display": "12 Jul 2026 19:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene (NGNE) CFO sells 4,800 shares and retains 84,040 including RSUs", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPbGVEUmI0bW9YRWM0eXJQXzMzTnZfdkZEVkNXVW5WQUFFekZGZjJ2VDcwTEIzZ214MWpWNGVwVTYtT3djZjJ2NXZ4Wm85LXBBYktpb2h2c0Y0Tm5QelFqMlJUSlphSlpUUGdhZ2dJU0NLU2lhYW5vTUhmTkpzeGdyMVdGRDhJTEFSR3RMQk5ZMkVWT21Od0JxX3pueG9rb0NNcEdYY0dxS0NaMHM?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T01:20:28+00:00", "published_display": "08 Jul 2026 01:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/neurogene-announces-inducement-grants-under-200100094.html", "source_name": "Business Wire", "published_at": "2026-07-06T20:01:00+00:00", "published_display": "06 Jul 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene lures 6 new hires with stock options tied to July 6 close", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPaFE1NFJmRWpGbnZGQ3l3bWEzQWdpVUl4OUx1MkxEa3VEUFJHLTY1OExfeTJ3YXIzSXpTanpYQXZfbVZsemZBZ0pxRVZ6d1lZcUx3dURjLUpMZlRvbmFHNGhwLUU4UzBNOFBhMmh6M3NhdkljWjNlZFJxVE9rYkdieVRvZXRvZkx0ci10OXNQUlNGVEloTll4VUk3cm9pZlRQVk1ZeVh0V0JzRU1mSDQtZ0hjV3BVTndjNGxkNXJrUGI?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Neurogene Inc. \u2013 NASDAQ:NGNE", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNQ0dHUWdJRHFtRmtTUDdHVHdwMF9Eczlrd1VwYVY2d2gtSlh1ZGY1OHF3c3NpY0hoR2hOTzhEalBLdEl5SkNUS3JwZHhwendGTzNhVWNEVGtPTnlORU5Rb19oMkt1SkhKUXJ4Y0YxbmZGMnlySGVDWC1BYnJZRVFoaEthNTRlTzY5U1plZ2FjSGhkR3QtTm1aVElLUlJFeDIwOFpacUFOUDR1Wmdm?oc=5", "source_name": "TradingView", "published_at": "2026-07-04T12:01:04+00:00", "published_display": "04 Jul 2026 12:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene (NGNE) secures $134.8M, extending cash runway into 2029", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPNXE4SEtJZDJIazJJNk8xOTYxVWtVQWlZNmVJZENkQm96MFhPVlRKY0lRTkFUVGp5YUE5NkQ0NTJBcF9EQ25tVmxka1QwSUctcmVMZjlSRGdtRUZERVYwSnNkOHBSUW1icVhjWlpyUG5BWjh1T0pLRG5Oc0ZzQjg0RXF3RTMwM3RhRHB5ajZFeEtSb3VkdUZxWEhMVnY4ZTZ6R1hENA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene (NGNE) CFO\u2019s 4,800-share sale under 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNS29TdXltbEFTRkdRRGR3Nlp1UTNuQ3V3WEl0ekFWbThkcmpJVDVSWFRsaTNfbG8zLWNURUx1ckl6eUpnd3A5N3N4Q0tUM2U4ZXVfcFd3WWlxMlVMNjhIOENDNEhadGRCTXNaREYybWI3MDNhUjBUYURlQlVDZjlzOUZQSFV6eXVDZTloWVZlNXdoVnZGaHB6VWl5ZHRmYXdTWTV5aEd1ZlVjZ3M?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price-Driven Insight from (NGNE) for Rule-Based Strategy", "summary": "This article provides a price-driven insight for Neoleukin Therapeutics Inc. (NASDAQ: NGNE) based on AI-generated signals for July 01, 2026. It highlights strong sentiment supporting an overweight bias, an ongoing breakout, and no resistance levels above the current price. The an", "url": "https://news.stocktradersdaily.com/news_release/39/Price-Driven_Insight_from_NGNE_for_Rule-Based_Strategy_070126064601_1782945961.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-01T19:09:11", "published_display": "01 Jul 2026 19:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene Prices $125 Million Public Offering", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/neurogene-prices-125-million-public-115119968.html", "source_name": "MT Newswires", "published_at": "2026-07-01T11:51:19+00:00", "published_display": "01 Jul 2026 11:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene Inc. Announces Pricing of $125 Million Public Offering", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/neurogene-inc-announces-pricing-125-110000050.html", "source_name": "Business Wire", "published_at": "2026-07-01T11:00:00+00:00", "published_display": "01 Jul 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene (NGNE) sells 3.5M shares, pre-funded warrants in $117M deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPUGZwWGpwc3RpMmhWVmZQNm1GVFlGdHNRalQ1MW1kYWxTei11TUVLT2hFcGU2ZERNNldvb0dVOUg5SWJ5aXRDTTJRMGFNRjhWU2ktcHJxVE9adWFDNk1lOEh0dFFJcVFVNEVkRlE2RXpRejk4RU5tejV5X2Qyc3puZHhSdUJCaHdBOS1VdTJMcXlrUDVXRUNoaWFrdGMzajFHeGk2bWJZOFU0UnhhUHRWRnNhU01uQmFGUjdN?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene Inc. (NGNE) Discusses Updated Phase 1/2 Data for NGN-401 Gene Therapy in Rett Syndrome - Slideshow", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOYXpWdUdqUnlWMklpTTZBZnV2VF9LdVIzeE00TThnODJnZzdKbXExMlFGbXNnZVc4Skh0cjdJTkg5NHBCaml0ZFJFX2FRdkc4VTdRSVJ0c2ZSdmRPWjN1ZUY1a0E1T2pUVloxdmpaa1RTWjBjc3JxeWV6SFY5RkhDUndOSnBuWkdjTTlvdVRSVndiZmtaRDdzUDVjOW1USE9BN0JYNFk3bDQ3ZHl1SGpySThzRmJBdE9BUUs2Z1N5bGxhcXNyN2FXUDdR?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene locks in $125M stock sale, closing expected July 2", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOR2twa2hIeE84MlRhWHI2dm5UOXRlUUtfbDVNVjhLb1NxZTZfRjVIZ0NNWFdzemR1ZE5iQTlsNUE1YXVoSW1CZnM4Q2VDYkFIVlFRT3hZejJyUU0zVDAxQTkyX0xqQ0dBSllIS3RUN25pckFHdFZHZG9WbkRtbjRpTjNmVjNEZkdlRGFTaHVucVlzcXo1UFM0UXYxZkZlUEFUeTNlS0NzN3Y0OS1M?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene Launches Public Offering", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/neurogene-launches-public-offering-202515977.html", "source_name": "MT Newswires", "published_at": "2026-06-30T20:25:15+00:00", "published_display": "30 Jun 2026 20:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene Inc. Announces Proposed Public Offering", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/neurogene-inc-announces-proposed-public-200100179.html", "source_name": "Business Wire", "published_at": "2026-06-30T20:01:00+00:00", "published_display": "30 Jun 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene seeks new funding for NGN-401 development", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPYnJFZC1GYW14bS1rY3hYb1JvczAzQkFPM3h2b3hkbTZXcTJlcTNycnZoUGFac2xEQnhZWWJ1VkFxaVA0NXRKT1BMN3dmRXdhdVl6TkNURVNWMkNBdlpyaWF3NzRMQXd3bkJXOU1QVC1JNVhSeTIxMDNMb1A2U0ItOFliaTRydUhyWHcyWUJGNWlXV0thcXcwTGxR?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene stock falls on public offering announcement", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOV0RRT3BWOHhhc3JkbGFCVTljXzE3YUZnbWtwdjhVY29sRnNtSk9VZ3FsdUpLRHpyRkFTaW53ZnZKbWRQTEVPRVFQazQ5X1ZrNXFCVXhDVnJXcWN2aUsxalE3Y0dCZ1VzSTZackxycENWcFhxVjJiVWZPelZLWnVuQ1I5Q3RHMDVGd01HLUlYak1NZXhSTGU1SnhleXp0SFpsNXQ5cHJteDl5aUk3NURWUklqUTZ2dw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/neurogene-reports-positive-long-term-110000835.html", "source_name": "Business Wire", "published_at": "2026-06-29T11:00:00+00:00", "published_display": "29 Jun 2026 11:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NGNE SEC Filings - Neurogene 10-K, 10-Q, 8-K Forms", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE1OX0t4c3F1TkdSc3ZfSndUenZzY2Rxbm1Vejh5UjM0X3Q5UHFNXzI3MXBRcjJQa2ljTkpCYlpPbWhzVV9DWEtNT01QTGRQWTA2R0htbHlCcklNZzh2ejJwcXJ4R1hHdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-21T08:43:54+00:00", "published_display": "21 Jun 2026 08:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(NGNE) Price Dynamics and Execution-Aware Positioning", "summary": "This article analyzes Neoleukin Therapeutics Inc. (NASDAQ: NGNE), highlighting strong sentiment across all horizons supporting an overweight bias. It outlines detailed institutional trading strategies, including long, momentum breakout, and short setups, with specific entry, targ", "url": "https://news.stocktradersdaily.com/news_release/1/NGNE_Price_Dynamics_and_Execution-Aware_Positioning_062026053402_1781991242.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-20T17:34:00", "published_display": "20 Jun 2026 17:34", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene (NGNE) director receives 12,050 fully vested stock options at $20.40", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQSU1IZWpkcmxDd3AtRmVMcS1paW12US15V0ExSXBFclBsaUtzbFhrajB5WUF4ZGI3TDh2azE4RFduRkNSeXcxVDFQVjEtVTl2aHEzMkZ3Qy1vYU1Jc1ZMVGJhQ2NqM2h5YndVOXVVV1U5TmZ0VHpXLUxBbG8zdG83SFR3czI2U2RYZndLZ0R3MHpnNWFablBRMHB1YkRuaEZ1bVIzMm5zTXdiTTVPb1lBU3g2RUs0ZFdX?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene Completes Enrollment in Embolden Trial of NGN-401", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/neurogene-completes-enrollment-embolden-trial-125433618.html", "source_name": "MT Newswires", "published_at": "2026-06-08T12:54:33+00:00", "published_display": "08 Jun 2026 12:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene Announces Successful Completion of Dosing in Embolden\u2122 Registrational Trial of NGN-401 for Rett Syndrome", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/neurogene-announces-successful-completion-dosing-113000090.html", "source_name": "Business Wire", "published_at": "2026-06-08T11:30:00+00:00", "published_display": "08 Jun 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "25 girls receive Neurogene\u2019s one-time gene therapy in key Rett syndrome trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPcktySlpxN2Z6a3laRWF4ZDZPR3dZbjZsTVc3RDJVakZoYlA5cVlaaTVDRVBKTW5kbXJucFNJc1BuUlNtUTRzSmJNTG02OVF1Q1dtUG41UVY2U0JRZnVLRzgxU1JjSlZydnExdi1XWUk3blBNdkVuR1c4b1N4d3h6eTVyME1YVExlWjBLMk5SOFpzakZSTGJRcF9NQm5McVJwSnNHRnJMMHRkRUJObWhRYTg3MW5fRl9FZ05rZmt3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two new Neurogene hires get options on 17,045 company shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPYmt3RGZaWG9BaWpmX1IzeE5TWEpQRjM2LTFMNE8yN1JzZDdSU09uN3o5cHViQVlrSU1zbTNiTmotbjF0QkptbDNEeDdlR2ZldGtNT1FXaGVfaXVBdXdlV1p4RmFRZ2hNcWVmOW5teFdaQjdGRlp6dzZmRG9MbXdrTHI2TGYzbjBfd1dwODBUQlpFR3hqUU1kMWlaQ2xscURjajZFR2xLVzVobGMzRVg2dVJ4RmJSWmVJNkJzbi1FM3c?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(NGNE) Movement as an Input in Quant Signal Sets", "summary": "This article analyzes Neoleukin Therapeutics Inc. (NASDAQ: NGNE) using AI models, indicating a neutral near-term outlook with potential mid-term strong sentiment stalling. It highlights a significant short setup with a 79.2:1 risk-reward ratio, targeting a 23.2% downside. The rep", "url": "https://news.stocktradersdaily.com/news_release/90/NGNE_Movement_as_an_Input_in_Quant_Signal_Sets_051826014802_1779126482.html", "source_name": "Stock Traders Daily", "published_at": "2026-05-18T13:48:00", "published_display": "18 May 2026 13:48", "sentiment": "negative", "sentiment_pct": 38, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene Inc. Stock 12\u2011Month Price Target Raised to $77.86, Implies 147% Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNTzZZaFlGVUhWMjRlU2dfcW1JQnNBc0sxR290ZUNqdTRsN2NsdE40ZzNXS01GeDg0U0pNRV9XalRpaTFqM2ktVEc2TDFubGd0V1V6X014UU9MUEVHZDF6RVF2Vkx1OVF0d2lwU3NidWRDMks3SE85emtOcTZlMUxFQUsxZWFTTkRlSnhLMEFlZWpQMGVVZ1RKWUlESzRRVlFnRkNoTW5TN2wteW1DbUotaW1iZF9Id0FVZ3paQnMwRnl3dU56dE8zYVBDdDZZaWFKMl9oQg?oc=5", "source_name": "TradingView", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 80, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/news/neurogene-q1-earnings-snapshot-202515103.html", "source_name": "Associated Press", "published_at": "2026-05-12T20:25:15+00:00", "published_display": "12 May 2026 20:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene Insider Sold Shares Worth $300,043, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/neurogene-insider-sold-shares-worth-155621031.html", "source_name": "MT Newswires", "published_at": "2026-05-08T15:56:21+00:00", "published_display": "08 May 2026 15:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene (NGNE) CFO executes 9,600-share 10b5-1 stock sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQcEtsdFFOU1gxTENzdExEVGUwT2JPSW1mZE5GalpPdXZUaWVLUFpld0JhUGtjbTdlVW1uNVNQZHlTWDhZTzVqWHh1cEE5cENNYjAxQTQtZHF1QXVLSGhfd2RxYWVad29oQVhkcXFuenNMNUwtSFAxS284ZndqanpsckpTcWNMWWpJemF6OTdlV3drTC1Nb2J4VWxWS3ZaMDlpNE1FdkZBZlBtRk0?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liquidity Mapping Around (NGNE) Price Events", "summary": "This article from Stock Traders Daily provides a detailed analysis of Neoleukin Therapeutics Inc. (NASDAQ: NGNE) price events. It highlights the potential for sustained positive sentiment, notes elevated downside risk due to a lack of long-term support, and outlines institutional", "url": "https://news.stocktradersdaily.com/news_release/98/Liquidity_Mapping_Around_NGNE_Price_Events_050726124002_1778172002.html", "source_name": "Stock Traders Daily", "published_at": "2026-05-07T12:40:06", "published_display": "07 May 2026 12:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene (NGNE) CCO granted 120,000 non-qualified stock options at $28.94", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNeWN5MFFBQ0RHSUFoS09wbUZpWmhzU0JaN3R0MzBwOExjRk5fRHVISi1CRmNQMVptellnM3p0TUNzMlFGZy1nZk1nNDZaSTY0ZS1wd3Z0YjFaSmV2OHBwUV94bTlQZUh1TUJpbmdmQkg2QUxJOWtvbVlvaFlJOFNjZ2RtSEpyd3kwSDB2bzRSYjhTNFVVeEdxN2FsUi1XNFo4aUxIQTZ6UzJSVUk?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cvijic to Sell 14,400 Neurogene Shares (NGNE) via J.P. Morgan", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPbmtaTkM2Mlh4bVVfdHJsZ3AwZ0t4WUJDRmgxdlV3Vkh3dnlHQWlEN081QWRmT1lycmRiV3V6VnB1MG96ckJxdjhkS3ZSR0hIREo0M1hsNWl3SmVDQzVJdG1wRjBPLXgtTTRZcEw2VTlUQmdTVC1iYTdJQ251aFVKQlZBTWItRHdsS194bWcybVpFUnZC?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Neurogene (NASDAQ:NGNE) Can Afford To Drive Business Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOUEw1dU1UaVV1bGZxNnVRNHY0U29iQnhkWVl4cHEwOW9QeHZRVWVpRVZteXJFYTBvOUhFQ1ctN0JJRzNqWS15MWhMbmFNRjFnUFRiM3Bwd0xieXlrd2FEUGdpT0ZEazktd0pQTFBKQkNPRkFoazF1UHBPU0NhRGFsQlFMbWVtU3k4Z3lMbFNnSXgtemI5b1ViNDhFZEdXZUs4?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like Neurogene (NASDAQ:NGNE) Are In A Position To Invest In Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxQX1hhWlF1ckNsaVI3SDlRT2xFWWp1ZF8yVjh0Nm9HOFlrbm1qQ0RsZ1FQbW5qb2llTWRkX0syazFSUnZpMk52RTJ0b0Q3TkU0eERwelRHWTM0TkdJZXpPczNmRHhlaHYxUERjVk9CNE1SZ0RhMENWOUdhMkYtSGZPbTZ5UC1pWjl6emxOckZOYkQta3dhRWozTy1HTE5JOEdnckxXQ18yd1BLZWVyWHFibVk3VWZwQlhtc2FnNVlwT3pYTmw5NzNOOEx4Wm4xUVJPblV4ZUVQYzllLW_SAeABQVVfeXFMTkFyTzg1NVdBN1NLejhhTHhUeWdZMGFrSUlaalhxbV9lcDBxeUNZY2hEbzRINkhNZEdTNDF3QWlLazZxTVVuTUE2cnpYSmh0c292MGNPenJyN3lRWVJOWEowQ0UtNTdfUjBMUkpiUmdnNkpIX0pWWjVOLUJKVnRmeU9nTTBGR1dLbXh6TU5weDJCbnpCYjRyckpvZUZuRlZEaFFMVjlhd1RLTW9xRHBVeHBuZE83eElqZnVHYTg1YnB1RF9EajVBOWJ6cUlwck16dWdkMTlLSktfbEZGTmRqU0w?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding Momentum Shifts in (NGNE)", "summary": "This article analyzes Neoleukin Therapeutics Inc. (NASDAQ: NGNE) using AI models to identify momentum shifts. It highlights weak near-term sentiment challenging long-term strength and outlines three distinct trading strategies with specific entry, target, and stop-loss zones. The", "url": "https://news.stocktradersdaily.com/news_release/139/Understanding_Momentum_Shifts_in_NGNE_041526102402_1776263042.html", "source_name": "Stock Traders Daily", "published_at": "2026-04-15T10:24:00", "published_display": "15 Apr 2026 10:24", "sentiment": "negative", "sentiment_pct": 29, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Discipline and Rules-Based Execution in NGNE Response", "summary": "This article analyzes Neoleukin Therapeutics Inc. (NASDAQ: NGNE) using AI models to provide trading strategies. It notes weak near and mid-term sentiment but a strong long-term outlook, identifying an exceptional risk-reward setup. The analysis offers specific entry, target, and ", "url": "https://news.stocktradersdaily.com/news_release/14/Discipline_and_Rules-Based_Execution_in_NGNE_Response_032426080602_1774353962.html", "source_name": "Stock Traders Daily", "published_at": "2026-03-24T08:06:00", "published_display": "24 Mar 2026 08:06", "sentiment": "negative", "sentiment_pct": 40, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(NGNE) Movement Within Algorithmic Entry Frameworks", "summary": "The article provides an algorithmic analysis of Neoleukin Therapeutics Inc. (NASDAQ: NGNE), highlighting strong sentiment across all horizons and an overweight bias for the stock. It details various institutional trading strategies including position, momentum breakout, and risk ", "url": "https://news.stocktradersdaily.com/news_release/81/NGNE_Movement_Within_Algorithmic_Entry_Frameworks_030226045002_1772445002.html", "source_name": "Stock Traders Daily", "published_at": "2026-03-02T04:50:00", "published_display": "02 Mar 2026 04:50", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How (NGNE) Movements Inform Risk Allocation Models", "summary": "This article analyzes Neoleukin Therapeutics Inc. (NASDAQ: NGNE) using AI models, highlighting a mixed sentiment with positive near-term but weak mid-term outlook within a long-term strength context. It provides three distinct institutional trading strategies\u2014Position Trading, Mo", "url": "https://news.stocktradersdaily.com/news_release/24/How_NGNE_Movements_Inform_Risk_Allocation_Models_021926032201_1771489321.html", "source_name": "Stock Traders Daily", "published_at": "2026-02-19T03:22:00", "published_display": "19 Feb 2026 03:22", "sentiment": "positive", "sentiment_pct": 71, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(NGNE) and the Role of Price-Sensitive Allocations", "summary": "This article provides an AI-generated analysis of Neoleukin Therapeutics Inc. (NASDAQ: NGNE), highlighting weak near and mid-term sentiment but a strong long-term outlook. It presents three distinct institutional trading strategies\u2014Position Trading, Momentum Breakout, and Risk He", "url": "https://news.stocktradersdaily.com/news_release/78/NGNE_and_the_Role_of_Price-Sensitive_Allocations_011626115802_1768625883.html", "source_name": "Stock Traders Daily", "published_at": "2026-01-16T23:58:00", "published_display": "16 Jan 2026 23:58", "sentiment": "negative", "sentiment_pct": 38, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Responsive Playbooks and the NGNE Inflection", "summary": "This article provides an AI-driven analysis of Neoleukin Therapeutics Inc. (NASDAQ: NGNE), highlighting weak near-term sentiment despite potential long-term strength. It presents specific trading strategies (Position, Momentum Breakout, Risk Hedging) with entry, target, and stop-", "url": "https://news.stocktradersdaily.com/news_release/23/Responsive_Playbooks_and_the_NGNE_Inflection_010526105002_1767671402.html", "source_name": "Stock Traders Daily", "published_at": "2026-01-05T22:50:00", "published_display": "05 Jan 2026 22:50", "sentiment": "negative", "sentiment_pct": 30, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why (NGNE) Price Action Is Critical for Tactical Trading", "summary": "This article analyzes Neoleukin Therapeutics Inc. (NASDAQ: NGNE) price action, highlighting a strong near-term sentiment while a mid-channel oscillation pattern is in play. The analysis identifies an exceptional risk-reward short setup and outlines three distinct AI-generated tra", "url": "https://news.stocktradersdaily.com/news_release/39/Why_NGNE_Price_Action_Is_Critical_for_Tactical_Trading_121425073202_1765758722.html", "source_name": "Stock Traders Daily", "published_at": "2025-12-14T19:32:00", "published_display": "14 Dec 2025 19:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Behavioral Patterns of NGNE and Institutional Flows", "summary": "This article analyzes Neoleukin Therapeutics Inc. (NASDAQ: NGNE) using AI models, highlighting a near-term weak sentiment despite mid-term strength and a broader long-term weak bias. It identifies a significant risk-reward short setup with a target of 41.6% downside versus 0.3% r", "url": "https://news.stocktradersdaily.com/news_release/15/Behavioral_Patterns_of_NGNE_and_Institutional_Flows_102325015602_1761242162.html", "source_name": "Stock Traders Daily", "published_at": "2025-10-23T13:56:00", "published_display": "23 Oct 2025 13:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene Announces Oversubscribed $200 Million Private Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOcUdxZ1NTOWh5Tm9yZExSVGZiOVJnV0tfZ18talJibnNKTjVyQ2NhMlBKUHluZy1xanRUeXJ6N0ZIODlZRWlBeDJ5SkFwbDdvM0Q0bnRNNXUwMndBRW5vRlhHYno5TWdVZ2RzTC14YTBvN2htRmxmUllySkxBa2F1ZG51bHJyb0djb29UR3FkaC1VTUN0WG5SQUtwX2tZVUlfM1R5V280dzFibzB2U2hsNWo3MUx3QkljX2cxMFBIT2ZoUQ?oc=5", "source_name": "Business Wire", "published_at": "2024-11-04T08:00:00+00:00", "published_display": "04 Nov 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene Stock: Gene Therapy Specialist May Break Chain Of Failed Mergers (NASDAQ:NGNE)", "summary": "Neurogene Inc., a clinical-stage gene therapy company, has seen its share price rise significantly since its Nasdaq debut in December 2023. The company is advancing two drug candidates, NGN-401 for Rett Syndrome and NGN-101 for CLN5 Batten Disease, with key milestones anticipated", "url": "https://seekingalpha.com/article/4680543-neurogene-stock-gene-therapy-specialist-may-break-chain-of-failed-mergers", "source_name": "Seeking Alpha", "published_at": "2024-03-26T14:13:00", "published_display": "26 Mar 2024 14:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene (NGNE) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9FVVBSb3FQdzlGZjRwdkMtZF9NVnBZS0J3VVBpOHVrWTdrM1VlMzVuZmR5QWhseTFOOXlYX2RDcUFtdVlDaS1UVGx6dFRKVmlWajJCdnRiRllqZw?oc=5", "source_name": "MarketBeat", "published_at": "2023-12-26T19:49:16+00:00", "published_display": "26 Dec 2023 19:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million", "summary": "Neurogene announced the closing of its merger with Neoleukin Therapeutics and a concurrent oversubscribed private placement of $95 million. The newly combined company, trading on NASDAQ as \"NGNE,\" now has approximately $200 million in cash, which is expected to fund its operation", "url": "https://aijourn.com/neurogene-announces-closing-of-merger-with-neoleukin-therapeutics-and-concurrent-private-placement-of-95-million/", "source_name": "The AI Journal", "published_at": "2023-12-19T18:10:13", "published_display": "19 Dec 2023 18:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kahn Swick & Foti, LLC Investigates Merger of Neoleukin Therapeutics, Inc. - NLTX", "summary": "Kahn Swick & Foti, LLC (KSF), led by former Louisiana Attorney General Charles C. Foti, Jr., is investigating the proposed merger of Neoleukin Therapeutics, Inc. (NLTX) with Neurogene Inc. The investigation aims to determine if the merger adequately values Neoleukin and if the pr", "url": "https://markets.financialcontent.com/fatpitch.financials/article/bizwire-2023-7-25-neoleukin-therapeutics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-and-foti-llc-investigates-merger-of-neoleukin-therapeutics-inc-nltx", "source_name": "FinancialContent", "published_at": "2023-07-25T10:49:00", "published_display": "25 Jul 2023 10:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neoleukin Therapeutics To Merge With Neurogene: Creates Biotech Firm Focused On Genetic Medicines For Neu", "summary": "Neoleukin Therapeutics and Neurogene are merging to form a biotech firm focused on genetic medicines for neurological diseases. The combined company, to be named Neurogene Inc., will focus on advancing Neurogene's pipeline, including NGN-401 for Rett syndrome, and is expected to ", "url": "https://www.benzinga.com/general/biotech/23/07/33263292/neoleukin-therapeutics-to-merge-with-neurogene-creates-biotech-firm-focused-on-genetic-medicines-", "source_name": "Benzinga", "published_at": "2023-07-18T18:39:02", "published_display": "18 Jul 2023 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene and Neoleukin Announce Merger", "summary": "Neurogene Inc. and Neoleukin Therapeutics, Inc. have announced a definitive merger agreement, with the combined entity set to operate as \u201cNeurogene Inc.\u201d The merger also involves an oversubscribed US$95 million private financing, projecting approximately US$200 million in cash fo", "url": "https://www.pharmtech.com/view/neurogene-and-neoleukin-announce-merger", "source_name": "PharmTech.com", "published_at": "2023-07-18T14:11:09", "published_display": "18 Jul 2023 14:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurogene and Neoleukin Announce Definitive Merger Agreement", "summary": "Neurogene and Neoleukin Therapeutics have entered into a definitive merger agreement to form a Nasdaq-listed biotech company focused on genetic medicines for neurological diseases. The combined entity is expected to have approximately $200 million in cash, including a $95 million", "url": "https://www.globenewswire.com/news-release/2023/07/18/2706252/0/en/Neurogene-and-Neoleukin-Announce-Definitive-Merger-Agreement.html", "source_name": "GlobeNewswire", "published_at": "2023-07-18T07:39:08", "published_display": "18 Jul 2023 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 102, "total_relevant": 59, "sentiment_summary": {"positive": 13, "negative": 8, "neutral": 38, "score": 52, "total": 59, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 18.5, "count": 33}, {"event": "earnings", "label": "Earnings", "weight": 4.75, "count": 10}, {"event": "deals", "label": "Deals and strategy", "weight": 3.65, "count": 6}, {"event": "guidance", "label": "Guidance", "weight": 2.2, "count": 4}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}], "positive_events": 13, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 39.63, "latest_week": "2026-07-10", "one_week_move": 12.1, "four_week_move": 36.2, "twelve_week_move": 42.3, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.642839, "market_dynamics_buy_signal": false, "relative_strength": 45.840761, "fair_value_gap": 56.8, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 45.3191, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+12.1% over one week, +36.2% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 60, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 14}, {"label": "Stock Traders Daily", "count": 13}, {"label": "Market source", "count": 6}, {"label": "Business Wire", "count": 6}, {"label": "MT Newswires", "count": 4}, {"label": "TradingView", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Seeking Alpha", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 51}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 33}, {"label": "Earnings", "count": 10}, {"label": "Deals and strategy", "count": 6}, {"label": "Guidance", "count": 4}, {"label": "Analyst action", "count": 4}, {"label": "Balance sheet", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "51", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+12.1% over one week, +36.2% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "(NGNE) Volatility Zones as Tactical Triggers"}], "updated_at": "2026-07-16T00:44:36.795150+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}